Envestnet Asset Management Inc. Buys 11,768 Shares of Becton, Dickinson and Company $BDX

Key Points

• Envestnet Asset Management increased its Becton, Dickinson and Company stake by 1.1% in the second quarter, adding 11,768 shares and bringing its holdings to 1.04 million shares valued at approximately $156.8 million.
• Institutional investors own nearly 87% of BDX’s outstanding shares, with State Street increasing its position by 8.5% during the quarter.
• Analysts maintain a consensus “Hold” rating with an average price target of $187.67. BDX recently beat quarterly earnings and revenue estimates, while announcing a $1.05 quarterly dividend yielding about 2.3%.

Envestnet Asset Management Inc. increased its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,036,041 shares of the medical instruments supplier's stock after buying an additional 11,768 shares during the period. Envestnet Asset Management Inc. owned about 0.38% of Becton, Dickinson and Company worth $156,784,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Andra AP fonden acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth $9,629,000. State Street Corp lifted its stake in shares of Becton, Dickinson and Company by 8.5% in the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier's stock valued at $2,269,960,000 after purchasing an additional 1,177,256 shares during the period. Anchor Investment Management LLC boosted its holdings in Becton, Dickinson and Company by 249.6% during the second quarter. Anchor Investment Management LLC now owns 3,045 shares of the medical instruments supplier's stock worth $461,000 after buying an additional 2,174 shares in the last quarter. Smith Chas P & Associates PA Cpas grew its holdings in shares of Becton, Dickinson and Company by 54.1% in the 2nd quarter. Smith Chas P & Associates PA Cpas now owns 3,132 shares of the medical instruments supplier's stock worth $474,000 after acquiring an additional 1,100 shares during the period. Finally, Miramontes Capital LLC purchased a new position in shares of Becton, Dickinson and Company in the second quarter valued at $420,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on BDX. Piper Sandler raised their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Friday, August 7th. Royal Bank Of Canada raised their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a research note on Thursday, August 13th. Bank of America lifted their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Monday, August 31st. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $187.67.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $183.51 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company has a fifty day moving average price of $178.10 and a two-hundred day moving average price of $161.09. The company has a market cap of $50.56 billion, a PE ratio of 55.27, a P/E/G ratio of 12.63 and a beta of 0.21. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the previous year, the company posted $3.68 earnings per share. The business's revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Feld sold 165 shares of the business's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,830 shares of company stock worth $1,251,894 in the last 90 days. Corporate insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.